EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $25.38 Average PT from Analysts

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine research firms that are covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last year is $25.38.

A number of research firms recently weighed in on EYPT. Wall Street Zen raised shares of EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. Mizuho reduced their price objective on shares of EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research note on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, May 29th. Finally, Chardan Capital dropped their target price on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, May 8th.

Institutional Trading of EyePoint Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. RA Capital Management L.P. acquired a new stake in EyePoint Pharmaceuticals during the fourth quarter worth approximately $23,705,000. TCG Crossover Management LLC increased its holdings in EyePoint Pharmaceuticals by 287.3% in the 4th quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company's stock valued at $26,614,000 after buying an additional 2,650,000 shares during the period. Adage Capital Partners GP L.L.C. raised its position in EyePoint Pharmaceuticals by 51.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock valued at $42,838,000 after purchasing an additional 1,958,580 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of EyePoint Pharmaceuticals by 92.7% during the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock worth $27,620,000 after buying an additional 1,783,765 shares during the last quarter. Finally, Suvretta Capital Management LLC lifted its holdings in shares of EyePoint Pharmaceuticals by 31.1% in the fourth quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company's stock worth $50,534,000 after acquiring an additional 1,607,268 shares during the last quarter. Institutional investors own 99.41% of the company's stock.

EyePoint Pharmaceuticals Stock Down 4.3%

Shares of NASDAQ:EYPT traded down $0.40 during mid-day trading on Wednesday, reaching $8.81. 829,333 shares of the stock were exchanged, compared to its average volume of 816,499. The stock's 50 day simple moving average is $6.27 and its 200-day simple moving average is $6.92. EyePoint Pharmaceuticals has a one year low of $3.91 and a one year high of $13.99. The company has a market cap of $606.22 million, a P/E ratio of -4.41 and a beta of 1.61.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The firm had revenue of $24.50 million during the quarter, compared to the consensus estimate of $8.84 million. Analysts anticipate that EyePoint Pharmaceuticals will post -2.13 EPS for the current fiscal year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.